Close

CENTOGENE Extends Partnership With Takeda

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

LOTTE BIOLOGICS Enters Contract Manufacturing Collaboration

LOTTE BIOLOGICS, on September 1, 2025, announced that it...

Cook Medical Says Extra Tariff to Be Passed to US Customers

According to medical device firm Cook Medical, the costs...

FDA Aims to Decrease Animal Testing as Tech Gathers Pace

Drug developers are raising the adoption of AI technologies...

The Shift Towards Real-World Evidence Clinical Development

The fact remains that the pharmaceutical spectrum happens to...

Centogene N.V., a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today that it has extended its partnership with Takeda Pharmaceutical Company Limited  to diagnose patients with certain genetic disorders.

As part of the agreement, which has been extended until March 2022, CENTOGENE will continue providing access to genetic testing to patients around the world.

Andrin Oswald, M.D., CEO of CENTOGENE, said, “We are pleased to be extending our partnership with Takeda, which will allow us to continue diagnosing and connecting rare disease patients globally. There is still a lot of work to be done, but with each step, we are closer to bringing patients the life-saving medical solutions they need.”

In January 2015, CENTOGENE originally entered into an agreement with Shire Pharmaceuticals, which is now a subsidiary of Takeda Pharmaceutical Company Limited, to provide diagnostic testing capability to enhance early diagnosis of patients suffering from genetic rare diseases.

Latest stories

Related stories

LOTTE BIOLOGICS Enters Contract Manufacturing Collaboration

LOTTE BIOLOGICS, on September 1, 2025, announced that it...

Cook Medical Says Extra Tariff to Be Passed to US Customers

According to medical device firm Cook Medical, the costs...

FDA Aims to Decrease Animal Testing as Tech Gathers Pace

Drug developers are raising the adoption of AI technologies...

The Shift Towards Real-World Evidence Clinical Development

The fact remains that the pharmaceutical spectrum happens to...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back